← FDA DRUG APPROVALS

FDA ANDA · ANDA216805

VORICONAZOLE

Sponsor: ZHEJIANG POLY PHARM

APPLICATION
ANDA216805
TYPE
ANDA
ORIGINAL APPROVAL
2024-01-02
LATEST ACTION
2025-08-25
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

VORICONAZOLEPrescription
VORICONAZOLE 200MG/5ML · FOR SUSPENSION · ORAL

Approval history

2025-08-25Labeling · Supplement 1 · standardAP
2024-01-02UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →